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Abstract Obesity is associated with insulin resistance,
hypertension, and cardiovascular disease, but the mecha-
nisms underlying these associations are incompletely
understood. Microvascular dysfunction may play an impor-
tant role in the pathogenesis of both insulin resistance and
hypertension in obesity. Adipose tissue-derived substances
(adipokines) and especially inflammatory products of
adipose tissue control insulin sensitivity and vascular
function. In the past years, adipose tissue associated with
the vasculature, or perivascular adipose tissue (PAT), has
been shown to produce a variety of adipokines that
contribute to regulation of vascular tone and local inflam-
mation. This review describes our current understanding of
the mechanisms linking perivascular adipose tissue to
vascular function, inflammation, and insulin resistance.
Furthermore, we will discuss mechanisms controlling the
quantity and adipokines secretion by PAT.
Keywords Obesity.Insulin resistance.Intracellular
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Introduction
Obesity is recognized as one of the major current
challenges to health care in Western societies. This is
due to its high and increasing prevalence and the
associated risk of type 2 diabetes and cardiovascular
disease. The hallmark of obesity, an increased mass of
adipose tissue, has triggered a wave of interest in the
physiologic and pathophysiologic functions of adipose
tissue. These functions depend on the quantity, location,
consistency, and bioactive products of adipose tissue. In
this review, we will consider the biology of adipose
tissue at a very relevant location for regulation of tissue
perfusion and blood pressure, the vasculature. We have
previously proposed that signaling from perivascular
adipose tissue (PAT) to the vasculature (“vasocrine”
signaling) may not only cause vascular disease associated
with obesity, but also reduce insulin-induced glucose
disposal by reducing muscle perfusion. In recent years,
evidence has emerged suggesting that this PAT may hold
one of the keys to effective future treatment or
prevention of both insulin resistance and cardiovascular
disease in obesity. This review aims to summarize and
evaluate this evidence.
Location, Origin, and Cellular Composition of PAT
Throughout the body, most arteries and veins with a
diameter greater than 100 μm are in contact with/
surrounded by adipocytes. The term “perivascular adipose
tissue” refers to adipose tissue around vessels, irrespective
of location. Known locations of PAT include the coronaries
(epicardial adipose tissue) [1], aorta (periaortic adipose
tissue) [2], and the microvascular beds of the mesentery [3],
muscle [4], kidney [5], and adipose tissue [6￿￿].
PAT consists of adipocytes, fibroblasts, stem cells [7],
mast cells [8, 9], and nerves [8]. PAT is initially formed in
the embryological phase and remains in place throughout
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expands and undergoes an inflammatory transformation.
In the first phase, which mainly takes place in utero, PAT is
assumed to form from mesoderm in association with the
developing blood vessels [10]. We will not further discuss
this phase in detail here, as the pathophysiologic growth of
PAT associated with vascular dysfunction mainly occurs in
adults. The volume of PAT is associated with the quantity
of intra-abdominal adipose tissue [11, 12￿￿].
The mechanisms involved in the expansion of PAT
involve differentiation of resident mesenchymal stem cells/
preadipocytes as well as infiltration and differentiation of
stem cells from bone marrow. The conversion of stem cells/
preadipocytes to adipocytes can be triggered by activation
of peroxisome proliferator-activated receptor-γ (PPAR-γ)
[13], and can be inhibited by the Wnt signaling pathway
and preadipocyte factor 1 (pref-1) [14]. Interestingly, mast
cells have recently been shown to control adipose tissue
expansion as well as insulin sensitivity [15]. This adipogenic
effect of mast cells is likely to be mediated by PPAR-γ,a s
mast cells are a known source of the natural PPAR-γ
activator 15d-PGJ2 [16].
Infiltration of PAT by immune cells such as macrophages
and T lymphocytes has been demonstrated in periaortic
adipose tissue in obesity and atherosclerosis [2, 17, 18].
The accumulation of T lymphocytes may trigger further
expansion of PAT because T cells, like mast cells, stimulate
adipogenesis by production of 15d-PGJ2 and activating
PPAR-γ [17]. Macrophages do not affect the quantity of
PAT, but produce cytokines that alter the secretion of
adipokines by PAT. Accumulating evidence suggests that
the products of PAT (ie, adipokines) contribute to regulation
of vascular function. In this regard, both protective physio-
logic and pathologic properties of PAT have been proposed.
Adipokines
Adipokines, initially described as adipose tissue-derived
cytokines, are now known as a large and diverse group of
substances with endocrine or paracrine functions secreted
by adipose tissue. These substances, comprising hormones,
cytokines, chemokines, and fatty acids, can be secreted by
adipocytes, but also by macrophages, mast cells, or other
cells within adipose tissue. In recent years, PAT has been
shown to secrete a variety of adipokines (Fig. 1). The rate
of excretion of various adipokines differs between PAT and
other adipose tissue depots, and may vary between PAT at
different sites in the vascular tree [6￿￿, 19￿￿]. Adipokines
such as fatty acids, tumor necrosis factor-α (TNF-α), and
adiponectin have been shown to affect insulin sensitivity,
but also inflammatory responses, appetite, atherosclerosis,
and hemostasis [20].
Adiponectin
Adiponectin is an abundant protein in the human circulation
that has been shown to be inversely associated with risk for
type 2 diabetes, to increase insulin sensitivity, and to
improve vascular function [21, 22]. Adiponectin expression
is limited to adipose tissue, but paradoxically, its levels are
decreased in obesity. This defect has been proposed to be
caused by TNF-α and interleukin (IL)-6, as well as other
inflammatory mediators [20]. Adiponectin itself can reduce
production of proinflammatory cytokines, and favorably
affects insulin signaling pathways [23].
Adiponectin occurs in a low molecular weight, middle
molecular weight, and a high molecular weight form in the
circulation, but it is not fully clear yet which form carries
the highest biological activity. It has been shown that PAT
in the heart [24] and in adipose tissue produces adiponectin
[6￿￿]. In subjects with coronary artery disease, production
of adiponectin is reduced in epicardial adipose tissue [25].
The secretion of adiponectin by differentiated perivascular
adipocytes, obtained from the coronaries of human organ
donors, remained much lower during a 24-day course when
compared with subcutaneous and perirenal adipocytes,
suggesting that PAT would have a more inflammatory
profile than other fat depots [19￿￿]. Conversely, another
study has reported similar concentrations of adiponectin in
PAT, subcutaneous and abdominal visceral adipose tissue
[26]. However, in the latter study adiponectin was measured
in homogenates of the adipose depots, and synthesis does
not necessarily equal secretion.
Fig. 1 Interaction of perivascular adipose tissue with vascular
endothelium, smooth muscle, and immune cells and the mediators
involved. ADRF adventitia-derived relaxing factor; Ang II angiotensin
II; IL-8 interleukin-8; MCP-1 monocyte chemoattractant protein 1;
ROS reactive oxygen species
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Leptin, the product of the ob gene discovered in 1994, is
one of the best known adipokines. Deficiency of leptin
activity leads to severe insulin resistance and vascular
dysfunction in mice and rats [27, 28], showing that leptin
controls metabolism and vascular function. Leptin has
been shown to increase nitric oxide (NO) production in the
presence of insulin [29]. Circulating levels of leptin are
increased in obesity, but resistance to leptin’s effects has
been proposed to decrease leptin activity in obesity.
PAT expresses leptin, although to a somewhat lower
extent than subcutaneous and perirenal adipose tissue,
and leptin secretion increases during diet-induced obesity
[19￿￿, 30].
Cytokines and Chemokines
A substantial number of studies have shown that PAT is a
source of, predominantly proinflammatory, cytokines and
chemokines [1, 9, 31], Mazurek et al. [1] found that
epicardial PAT from 42 patients who underwent elective
coronary artery bypass graft s u r g e r ye x c r e t e dh i g h e r
amounts of IL-1β, IL-6, IL-6sR, and TNF-α than
subcutaneous adipose tissue from these same patients. In
another study, IL-6 and IL-8 excretion in differentiated
perivascular adipocytes was higher than in subcutaneous
and perirenal fat, as well as monocyte chemoattractant
protein 1 (MCP-1) release [19￿￿]. Importantly, the amount
of cytokines excreted by PAT did not correlate with
plasma cytokine concentrations. These findings illustrate
the importance of adipose tissue location and that systemic
concentrations of adipokines may not be representative of
local concentrations in tissues. Also, the inflammatory
properties of epicardial adipose tissue were independent of
obesity [1].
Aside from cytokines, PAT is also a source of
chemokines such as IL-8, MCP-1, and RANTES [31,
32]. These have been implicated in the initiation of
vessel wall inflammation and concomitant production of
cytokines.
Adventitia-derived Relaxing Factor
PAT surrounding the aorta and mesenteric arteries of rats
[3, 33] has been shown to exert a direct relaxing effect on
vascular smooth muscle, mediated by one or more
adventitia-derived relaxing factors (ADRFs). One of these
ADRFs has been identified as angiotensin 1–7[ 34]. It is
not known yet whether ADRFs are expressed by human
PAT.
Renin-Angiotensin System
PAT has been shown to express all components of the
renin-angiotensin system except renin [35], and has
been implicated in the pathogenesis of hypertension.
Interestingly, angiotensin production by mesenteric adipose
tissue was found to be higher than that in periaortic adipose
tissue, showing regional differences in this system [35].
Reactive Oxygen Species
Production of reactive oxygen species by PAT has primarily
been found in the larger arteries of rats and mice. Reactive
oxygen species production in PAT is produced by NADPH
oxidase in immune cells [32, 36], can be increased by
angiotensin [32], and has been found to be increased in
experimental obesity [36].
Vasoactive Properties of PAT
Accumulating evidence suggests that the products of PAT
contribute to regulation of vascular function. Moreover,
vascular function, specifically microvascular functions such
as tissue perfusion, contributes to the regulation of insulin
sensitivity [37]. Here, we will discuss the effect of PAT on
vascular function.
No data have been published directly linking insulin-
induced vasoreactivity, a contributor to insulin-mediated
glucose uptake, to the phenotypical characteristics of PAT.
It has nevertheless been hypothesized that PAT does
influence insulin-induced vasoreactivity [4]. Moreover,
there are numerous studies that report on the important
role PAT has in vascular tone regulation. The vasoactive
properties of PAT have been studied in the aorta and other
large vessels, but also in the microcirculation [6￿￿].
PAT and Endothelium-dependent Vasodilation
Endothelium is an important modifier of vascular tone and
recent evidence suggests PAT alters the balance between
endothelium-dependent vasodilator and vasoconstrictor
substances such as NO and endothelin-1 [38]. PAT could
modify vascular reactivity by secreting adipokines, some of
which are known to have an effect on vasoreactivity [39].
Because the profile of adipokines secreted by PAT alters
during adiposity, vascular reactivity may be altered as a
consequence [19￿￿]. The amount of PAT surrounding the
brachial artery is negatively associated with post-ischemic
increase in forearm blood flow, a measure of microvascular
dilation downstream, but not with vasodilation at the
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the microcirculation through a vasocrine mechanism, or
that PAT quantity around the brachial artery is associated
with the amount of PAT in the microcirculation [12￿￿].
Vascular dilation by glyceryl trinitrate administration also
was not affected, precluding a direct effect of PAT on
smooth muscle in this study [12￿￿]. The observation that
PAT does not have a local effect on local endothelial
function is contested by evidence from ex vivo studies. In
human internal thoracic arteries (ITAs), PAT has anticon-
tractile properties in the vasoconstrictor response to U
46619 (a thromboxane A2/prostaglandin H2 receptor ago-
nist), the concentration at which 50% of maximum
constriction is achieved is the same for the ITAs with and
without PAT, indicating that PAT attenuates maximum
contractility, but not sensitivity to U 46619 of the
endothelial cell. Endothelium-independent vasodilation
was not modified by PAT in this study [40]. Anticontractile
properties of PAT are not only seen in large arteries, but
also in the microcirculation [6￿￿].
PAT around microvessels derived from subcutaneous
gluteal fat of healthy lean subjects also possesses anticon-
tractile properties [6￿￿]. When a microvessel is exposed to
PAT-conditioned medium, it responds with relaxation, even
in the absence of an exogenous agonist. These anticon-
tractile properties are abrogated when a microvessel with
PAT is used from patients with metabolic syndrome,
suggesting functional differences between PAT from lean
subjects and subjects with metabolic syndrome. Moreover,
in response to norepinephrine, microvessels with PAT from
lean healthy subjects exhibit less vasoconstriction than
microvessels without PAT or PAT from patients with
metabolic syndrome. In a further set of experiments, the
anticontractile effects of PAT were abolished by scavenging
adiponectin with a soluble adiponectin-receptor 1 fragment.
These results point to a crucial role of adiponectin, an anti-
inflammatory adipokine. Also, hypoxic conditions, which
are known to decrease adiponectin production, attenuate the
anticontractile properties of PAT [6￿￿, 41]. When micro-
vessels with PAT from lean subjects are incubated with
TNF-α, which is a proinflammatory adipokine, the anti-
contractile effect is attenuated. However, blocking TNF-α
with infliximab in experiments with PAT from patients with
metabolic syndrome has no effect on microvascular tone.
The authors speculate that in obesity, perivascular adipo-
cytes increase in size, creating the hypoxic environment,
which decreases adiponectin production. The authors
acknowledge that other adipokines from the perivascular
adipocytes probably have additional effects [6￿￿]. A
drawback of this study is that even though the micro-
vessels used are harvested from humans, the micro-
vessels and PAT were harvested from gluteal fat biopsies.
Microvessels situated in a large depot of adipose tissue
may respond differently to PAT-derived adipokines than
microvessels in other tissues such as muscle and heart.
Moreover, these are all acute experiments and chronic
exposure to the factors secreted by PAT could have
different effects.
The anticontractile effects of PAT are also seen with
mesenteric arteries from lean New Zealand black (NZB)
mice, in which vasoconstriction in response to norepineph-
rine, endothelin, and angiotensin II is acutely blunted.
These anticontractile properties are abolished in the New
Zealand obese (NZO) mice. Conversely, PAT does not
affect vasodilation in response to acetylcholine or bradyki-
nin in either NZB or NZO mice [36].
PAT itself could be a source of NO, as PAT increases
diaminofluorescein (DAF) fluorescence, a marker of NO,
under stimulation of leptin after 8 weeks of a high-fat diet,
preserving vascular reactivity [42]. It should be noted that
nitric oxide synthase inhibitors were not used in combina-
tion with DAF in this study, and therefore DAF fluores-
cence may be caused by radicals other than NO. Leptin
could be a stimulator of NO production, but, in contrast,
epicardial PAT from swine with a diet-induced metabolic
syndrome excretes more leptin than epicardial PAT in lean
swine, and the increased production of leptin attenuates
endothelium-dependent vasodilation [30]. Moreover, endo-
thelial function can be restored by adding a leptin
antagonist. In this study, the authors only report on leptin
excretion by PAT, and not on other adipokines. Leptin
concentration in the mesenteric arteries in spontaneously
hypertensive rats (SHRs) is lower than in Wistar-Kyoto
(WKY) rats, but leptin causes more vascular relaxation in
SHRs. Leptin-induced relaxation is not modulated by PAT in
both WKYand SHRs [43]. Taken together, leptin released by
PAT may cause vasodilation or vasoconstriction, depending
on the location of PAT.
Remarkably, hyperglycemia potentiates the anticontrac-
tile effect of periaortic PAT on the endothelium in response
to phenylephrine [44]. In the presence of PAT acute
hyperglycemia blunts contraction of aortic rings on phen-
ylephrine in the presence of PAT, irrespective of the
presence of endothelium. When PAT is removed from the
aortic rings, acute hyperglycemia has no effect on reactivity
of the aorta to phenylephrine, irrespective of the presence of
endothelium.
Aortic rings with intact PAT and endothelium exhibit the
least contraction in response to phenylephrine, and aortic
rings stripped of both PAT and endothelium show the most
contraction. Aortic rings stripped of either PAT or endothe-
lium had intermediary responses. These results hold true for
control rats as well as streptozocin (STZ) rats, a model for
type 1 diabetes mellitus. Removal of PAT increases the
vasoconstrictor response to phenylephrine in STZ rats more
than in control rats, regardless of the presence of endothe-
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in the control and STZ rats, in both the presence, as well as
the absence, of endothelium [44].
Thus, PAT enhances endothelium-dependent vasodilation,
probably through adiponectin or leptin. Contrarily, leptin may
also enhance vascular constriction. The exact mechanisms
through which PAT modulates (micro-)vascular tone remain
to be investigated. Moreover, there not only seems to be an
endothelium-dependent effect, but also a direct effect on
smooth muscle function.
Direct Effect of PAT on Smooth Muscle Tone
Vasculartoneisnotonlyregulatedbytheendothelium,butthe
smooth muscle cells, which are responsible for vascular tone,
c a nb ed i r e c t l ya f f e c t e db yv a s o a c t i v es u b s t a n c e sa sw e l l .
In rodent models, PAT of the aorta and mesenteric bed
secretes a substance called ADRF (also called PVRF [PAT-
derived relaxing factor]) [45], which directly acts on smooth
muscle cells. At present it is not fully clear if there is one or
more ADRF and what the ADRF(s) are. The modulating
effect of ADRF on vascular reactivity is mediated by
potassium channels in the smooth muscle cells. Galvez et.
al. [43] performed experiments on PAT in WKY rats and
SHRs. In a perfused mesenteric bed, the perfusion pressure
increase is greater in WKY than in SHR after potassium
channel blockade with 4-aminopyridine (4-AP). The more
PAT is present, the larger the response to 4-AP. The increase
in perfusion pressure after potassium channel blockade
indicates that PAT secretes a potassium channel–dependent
anticontractile substance. Moreover, both sodium nitroprus-
side and acetylcholine decrease perfusion pressure in the
same magnitude in the perfused mesenteric bed of WKYand
SHR, which points to a smooth muscle cell effect, and not to
endothelium-dependent relaxation. In isolated mesenteric
arteries the vasoconstriction generated by serotonin is
blunted by PAT in both WKY as well as SHR [43], which
also points to smooth muscle cell dependency. The anticon-
tractile effect of PAT is greater in WKY, so that functional
changes in PAT may contribute to the higher arterial tone in
SHR [43]. In lipoatrophic mice, vascular constriction on
phenylephrine was aggravated in aortic rings compared with
wild-type mice, due to the absence of PAT. Perfusion
pressure in the mesenteric vascular bed was also increased
in response to phenylephrine [46].
Serotonin increases perfusion pressure more in perfused
mesenteric vascular beds of mice without PAT than in
perfused mesenteric vascular beds in the presence of PAT.
In adiponectin knockout mice PAT retained anticontractile
properties, thereby suggesting that adiponectin is not ADRF
[26]. However, when in experiments with human arteries,
adiponectin action is blocked through an adiponectin type 1
receptor fragment, the anticontractile properties of PAT are
completely attenuated [6￿￿]. One of the ADRFs recently
identified is angiotensin 1–7, which activates the Mas
receptor, resulting in vasorelaxation [34]. Whether angio-
tensin 1–7, or another ADRF, is secreted by human PAT,
and what its role is in vasoreactivity remains to be proven.
Thus, PAT has anticontractile properties, and some but
not all studies find that this effect is mediated by the
endothelium. Data on the functional change of PAT in
adiposity are not conclusive, but most studies find that
the anticontractile properties are lost in obesity.
PAT and Insulin Sensitivity
As mentioned above, vascular function and especially
microvascular blood volume in muscle are related to insulin
sensitivity. Because obesity is associated with insulin
resistance, reduction of microvascular blood volume, and
altered properties of PAT, we have proposed that PAT
causes microvascular dysfunction and insulin resistance in
obesity [4]. Although there are, at present, no studies that
prospectively link PAT to diabetes, a number of studies
provide indirect evidence for this hypothesis.
First, several studies suggest that ectopic adipose tissue,
especially within muscles, strongly relates to insulin
sensitivity.The amountofPATsurroundingthe brachialartery
[12￿￿] and adipose tissue between muscle (intermuscular
adipose tissue [IMAT]) [47] are inversely related to insulin
sensitivity. Even though IMAT accounts for only 3% of total
thigh adipose tissue, it has the strongest correlation with
insulin sensitivity in obese subjects and subjects with type 2
diabetes mellitus. After a 16-week weight loss program, the
IMAT compartment in the thigh decreased stronger than
subcutaneous fat and subfascial fat [48].
Second, vascular function, especially muscle perfusion,
contributes to regulation of insulin-mediated glucose
disposal. Increased amounts of adipose tissue, as observed
in obese subjects and rats, are accompanied by impairment
of muscle perfusion. Impairment of muscle perfusion has
been estimated to account for 30% to 50% of insulin
resistance [49].
Third, we have found accumulation of PAT around the
arterioles that regulate muscle perfusion. Aside from
intermuscular adipose tissue and PAT around the femoral
artery, we have found that PAT exists within muscles
(ie, intramuscular PAT [mPAT]) [unpublished data]. This
location is especially relevant given the increasing evidence
for regulation of muscle insulin sensitivity by microvascular
perfusion in muscle [49, 50]. By regulating endothelium-
dependent vasodilatation, insulin-mediated vasoreactivity,
and muscle perfusion, mPAT may control muscle glucose
uptake and, thus, determine risk of future type 2 diabetes.
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to be tested in future studies.
Taken together, these data support the hypothesis that
PAT is involved in the development of insulin resistance.
The strongest data for or against this hypothesis will likely
come from PAT-specific transgenic mouse models, but at
present such models do not exist.
Conclusions
PAT is increasingly recognized as a widespread, relevant
tissue in vascular biology and important determinant of
cardiovascular complications of obesity. Recent studies
have shown that PAT relates to endothelium-dependent
vasodilatation and inflammation by secreting a variety of
substances that affect vascular tone and infiltration of
inflammatory cells. The mechanisms controlling the quan-
tity of PAT and adipokine secretion from PAT remain to be
determined. Because PAT is related to insulin resistance,
controls vascular function, and is located within insulin
target tissues, it may well contribute to the pathogenesis of
type 2 diabetes as well as cardiovascular disease.
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